Tirzepatide

Scientific Overview

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist studied for type 2 diabetes and obesity.

Mechanism focus

Simultaneous GIP and GLP-1 receptor engagement amplifies incretin signaling relevant to insulin secretion, appetite regulation, and adipose/energy metabolism.

Research Use Cases

• Dual-incretin receptor pharmacology
• Obesity intervention model comparisons (SURMOUNT)
• Head-to-head incretin agonist studies (SURPASS vs semaglutide)
• Metabolic syndrome biomarker panels

Use-Case Study Notations

• Case-study notation: SURPASS-2 compared tirzepatide with semaglutide for glycemic endpoints in type 2 diabetes.
• Case-study notation: SURMOUNT-1 evaluated once-weekly tirzepatide for obesity treatment endpoints.
• Dual-agonist design requires careful peptide identity testing (MS/HPLC).

Selected Studies

1. 01 Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesPubMed 34170647
2. 02 Tirzepatide Once Weekly for the Treatment of ObesityPubMed 35658024
3. 03 Tirzepatide for Obesity Treatment and Diabetes PreventionPubMed 39536238
4. 04 Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity ManagementPubMed 36750526
5. 05 Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development programPubMed 36478180

Related compounds

Semaglutide · Retatrutide · AOD-9604